Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit until now.
On January 20, 2026, Moderna and Merck reported that their personalized mRNA vaccine combined with Keytruda cut melanoma recurrence or death risk by 49% at five years in a Phase 2b trial of 157 patients. The result matched the three-year mark, suggesting a lasting rather than temporary benefit.
The announcement triggered a 15% surge in Moderna's stock, establishing the company as a leader in personalized cancer vaccines. With the Phase 3 melanoma trial (INTerpath-001) fully enrolled and the parallel lung cancer trial (INTerpath-002) now recruiting, regulatory submissions are expected by late 2026. If Phase 3 replicates the durability seen in Phase 2b, patients could access the first personalized cancer vaccine by 2027, validating mRNA beyond infectious disease.
Why it matters
A positive Phase 3 puts a custom mRNA cancer vaccine on track for 2027 approval, testing whether personalized medicine can scale.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
42%
Phase 3 Risk Reduction
Recurrence or death risk reduction for intismeran plus Keytruda versus Keytruda alone after surgery
58%
Reduction After Six Months
Prespecified analysis after the immunization period in the Phase 3 trial
1,137
Phase 3 Patients
Patients with completely resected stage IIB-IV melanoma in INTerpath-001
99%
Manufacturing Success
Patients randomized to intismeran for whom the custom vaccine was successfully manufactured
17 events
Latest: October 2026
Showing 8 of 17
JK to step
Tap a bar to jump to that date
Jump to
October 2026
Phase 3 Melanoma Trial Meets Primary Endpoint
LatestData Release
INTerpath-001 reported a 42% reduction in recurrence or death (HR 0.58) after a median 24.6 months. The reduction reached 58% after the six-month immunization period.
April 2026
Pancreatic mRNA Vaccine Reports Six-Year Results
Data Release
A report on an early-stage pancreatic cancer mRNA vaccine said results lasted six years. The trial is separate from the Moderna-Merck melanoma program.
January 2026
Moderna Stock Surges 15% on Five-Year Data
Financial
Moderna shares jump 15% following announcement of sustained 49% risk reduction, with analysts projecting potential approval by 2027.
Five-Year Data: 49% Risk Reduction Holds
Data Release
Five-year follow-up confirms sustained 49% reduction in recurrence or death, with 75.3% recurrence-free survival versus 55.6% for Keytruda alone.
Phase 3 Melanoma Trial Fully Enrolled
Clinical Trial
INTerpath-001 completed enrollment; the trial ultimately included 1,137 patients, according to Moderna's Phase 3 report.
Bancel Frames Cancer Vaccine as Post-Pandemic Pivot
Strategic
At J.P. Morgan Healthcare Conference, Moderna CEO describes 2026 pipeline as 'full of catalysts' with cancer vaccine central to company's oncology transformation.
October 2024
Second Lung Cancer Phase 3 Trial Initiates
Clinical Trial
INTerpath-003 begins enrolling patients receiving mRNA-4157 as adjuvant therapy following neoadjuvant Keytruda and chemotherapy in resected NSCLC.
April 2024
Three-Year Data Confirms Durability
Data Release
Three-year follow-up shows 49% risk reduction maintained, suggesting durable immune reprogramming rather than temporary benefit.
December 2023
Lung Cancer Phase 3 INTerpath-002 Begins
Clinical Trial
Phase 3 trial initiates for adjuvant treatment of resected Stage II-IIIB non-small cell lung cancer, targeting disease-free survival endpoint.
July 2023
Phase 3 INTerpath-001 Initiates
Clinical Trial
Global Phase 3 trial begins, targeting 1,089 patients across 165+ sites in 25+ countries.
February 2023
FDA Grants Breakthrough Therapy Designation
Regulatory
FDA designates mRNA-4157 plus pembrolizumab as Breakthrough Therapy for adjuvant treatment of high-risk melanoma.
December 2022
Initial Results: 44% Risk Reduction
Data Release
Two-year follow-up data shows 44% reduction in recurrence or death risk, triggering FDA Breakthrough Therapy Designation application.
October 2022
Merck Exercises $250M Option
Financial
Merck pays $250 million to exercise its option for joint development and commercialization, splitting future costs and profits 50-50.
April 2019
KEYNOTE-942 Trial Begins
Clinical Trial
Phase 2b trial initiates enrollment, randomizing patients 2:1 to mRNA-4157 plus Keytruda versus Keytruda alone.
May 2018
Partnership Expands to Shared Antigens
Partnership
Moderna and Merck expand collaboration to include shared antigen mRNA cancer vaccines, including KRAS-targeting mRNA-5671.
January 2017
mRNA-4157 Development Begins
Development
Moderna initiates development of mRNA-4157, a personalized neoantigen therapy encoding up to 34 tumor-specific mutations.
January 2016
Moderna-Merck Partnership Begins
Partnership
Moderna and Merck form initial collaboration on personalized mRNA cancer vaccines, with Merck investing $125 million in Moderna equity.
Scenarios
1
Phase 3 Succeeds, FDA Approves by 2027
Likely
Discussed by: William Blair analysts, Moderna investor communications
INTerpath-001 replicates the Phase 2b results in a larger, more diverse population. Moderna and Merck file for FDA approval in late 2026, receiving approval in 2027 under accelerated review. The vaccine becomes standard of care for high-risk resected melanoma, generating several billion dollars annually and validating personalized mRNA oncology as a platform.
The Phase 3 trial shows a statistically significant but smaller benefit than Phase 2b—perhaps 25-35% risk reduction. FDA grants conditional approval with post-marketing requirements. Adoption is slower due to the manufacturing complexity (4-6 weeks per patient dose) and high projected cost ($100,000+), limiting initial use to specialized academic centers.
3
Phase 3 Fails, Development Continues in Other Cancers
INTerpath-001 fails to show statistical significance in the primary endpoint, echoing the troubled history of cancer vaccines. Moderna and Merck pivot to ongoing trials in lung cancer, kidney cancer, and bladder cancer, hoping different tumor types respond better. Stock prices decline sharply, but the platform survives in development.
Even with FDA approval, the requirement to sequence each patient's tumor and custom-manufacture each vaccine dose creates severe capacity constraints. The therapy launches but reaches only thousands of patients annually rather than the hundreds of thousands who could benefit, echoing the commercial struggles of Provenge.
Discussed by: J.P. Morgan analysts, Moderna investor relations
Phase 3 trials succeed in both melanoma and lung cancer, with FDA approving both indications in 2027-2028. The platform demonstrates efficacy across tumor types, validating the personalized neoantigen approach. Moderna and Merck expand into kidney, bladder, and other solid tumors, creating a multi-billion-dollar franchise that rivals Keytruda's peak sales.
6
FDA approves intismeran plus Keytruda by 2027
Likely
Resolves by End of 2027
Discussed by: Moderna CEO Stéphane Bancel, Reuters
Moderna says it is finishing a regulatory filing and aims for full approval in 2027. The FDA has not set a decision date. A positive Phase 3 result and Breakthrough Therapy Designation support an expedited review, but approval depends on the agency's review of the filing.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1 of 3
April 2010 - November 2014
Provenge (Sipuleucel-T) Approval and Dendreon Collapse (2010-2014)
The FDA approved Provenge, the first therapeutic cancer vaccine, for metastatic prostate cancer in 2010. Developed by Dendreon, it extended median survival by 4.1 months and was priced at $93,000 per treatment course. Despite the breakthrough, Dendreon filed for bankruptcy in 2014.
Then
Reimbursement confusion, complex three-week manufacturing process, and competition from simpler oral drugs limited adoption to a fraction of eligible patients.
Now
Provenge survives under new ownership, but the failure chilled cancer vaccine investment for years. It proved personalized cell therapy could win FDA approval—but commercial success requires more than clinical efficacy.
Why this matters now
The Moderna-Merck vaccine faces similar manufacturing complexity—each dose custom-made for each patient. The partnership structure (two large companies sharing costs) and simpler mRNA manufacturing may avoid Dendreon's fate, but the precedent looms.
2 of 3
2011 - Present
Checkpoint Inhibitor Revolution (2011-Present)
Ipilimumab's 2011 FDA approval for melanoma launched the checkpoint inhibitor era. Keytruda followed in 2014, eventually becoming the world's best-selling drug at $29.5 billion annually. Five-year melanoma survival rates jumped from 15-20% to 34-52% for advanced disease.
Then
Checkpoint inhibitors transformed melanoma from a death sentence to a manageable disease for many patients, though response rates plateau around 40-50%.
Now
Keytruda's 2028 patent expiration creates both urgency and opportunity for Merck—the mRNA vaccine could extend Keytruda's relevance and create a new combination standard of care.
Why this matters now
The mRNA vaccine builds on rather than replaces checkpoint inhibitors—it provides immune targeting while Keytruda removes immune brakes. Success would represent the next evolution, not a replacement, of immuno-oncology.
3 of 3
December 2020 - December 2021
COVID-19 mRNA Vaccine Validation (2020-2021)
Moderna's mRNA-1273 and BioNTech/Pfizer's BNT162b2 became the first mRNA vaccines approved for human use, delivering in under a year what typically takes a decade. Billions of doses administered proved the technology safe and manufacturable at scale.
Then
Moderna's market cap briefly exceeded $150 billion. The company gained manufacturing expertise, regulatory credibility, and billions in revenue.
Now
COVID success validated mRNA as a platform but left an existential question: could the technology work beyond infectious disease? Cancer is the proving ground.
Why this matters now
The pandemic built the infrastructure, expertise, and investor confidence now being deployed against cancer. But cancer vaccines require personalization that COVID vaccines did not—a harder manufacturing and regulatory challenge.
